HIMSHims & Hers Health, Inc.

Company: Hims & Hers Health, Inc. (NYSE: HIMS) Filing: 10-Q | Filed with the SEC on November 9, 2026 Current Price: $19.64 | Today's Change: -14.40%

---

What Happened

Hims & Hers Health filed its quarterly report (10-Q) with the SEC on November 9, 2026, covering the third quarter of fiscal year 2026. The company reported revenue of $1.729 billion for Q3 FY2026, alongside net income of $49.5 million and operating income of $96.4 million. Diluted earnings per share came in at $0.43, with basic EPS at $0.48, representing a profitable quarter on both top and bottom lines.

---

Why It Matters

Despite a quarter that shows clear profitability — operating income of $96.4 million and positive net income — HIMS shares are down sharply by 14.40% on the day of this report. This divergence between headline financial figures and market reaction is notable. For investors, the practical near-term question is not whether the company is profitable (the filing confirms it is), but whether the pace of growth, margins, or forward guidance embedded in or alongside this filing met elevated market expectations. The steep share-price decline suggests the market found something in the full filing — whether in sequential revenue trends, cost structure, or management commentary — that disappointed relative to consensus. With revenue at $1.729 billion for a single quarter, the absolute scale of the business is not in dispute; it is the trajectory that investors appear to be repricing.

---

Analysis

The numbers themselves tell a story of a company that has scaled into genuine profitability: operating income of $96.4 million on $1.729 billion of revenue implies an operating margin of roughly 5.6%, and net income of $49.5 million confirms the bottom line is positive. This is a meaningful milestone for a company that spent much of its early history posting losses.

However, the market's -14.4% reaction is a sharp reminder that in high-growth, high-valuation consumer health names, reported results are always measured against expectation — not in isolation. Several things are worth watching:

• Revenue run-rate: At $1.729 billion in a single quarter, the annualized revenue run-rate implied is substantial, but the market will be scrutinizing whether growth is accelerating, stable, or beginning to decelerate.
• Operating vs. net income gap: Operating income of $96.4 million versus net income of $49.5 million points to meaningful below-the-line charges (interest, taxes, or other items) that narrow the take-home profitability — worth monitoring in the full filing.
• Margin trajectory: A 5.6% operating margin at this revenue scale leaves room for expansion — or compression — and the direction matters enormously to valuation.

StockWatch initiated coverage on HIMS on September 22, 2026. The sharp post-filing price move is likely to inform any forward reassessment of the company's near-term operating outlook; readers should consult the full initiating coverage for broader context on the investment thesis.

---

Disclaimer

This report is a news and informational summary based solely on data extracted from Hims & Hers Health's SEC filing and publicly available market data. It does not constitute investment advice, a recommendation to buy or sell any security, or a research rating of any kind. Investors should conduct their own due diligence and consult a qualified financial adviser before making any investment decisions.

Existing Coverage

StockWatch has full coverage on HIMS, published 2026-09-22. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-09. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1773751/000177375126000246/hims-20260930.htm